Collectively, our findings demonstrated PGD2 and CRTH2 as novel prognostic biomarkers and therapeutic targets in DLBCL, and highlighted the potency of high-concentration PGD2 as a promising therapeutic strategy for DLBCL patients. This evidence concerns the gene PTGDR2 and diffuse large B-cell lymphoma.